No Data
No Data
Citigroup Maintains Buy on 10x Genomics, Lowers Price Target to $15
10x Genomics Analyst Ratings
Citi Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $15
Express News | 10X Genomics: Co's Litigation Against Parse's Gene Expression Products Remains Ongoing
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
Insider Spends US$446k Buying More Shares In 10x Genomics